1-(3-Fluorobenzyl)-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride | 120013-40-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(3-Fluorobenzyl)-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride
• 英文别名: 2-[[1-[(3-Fluorophenyl)methyl]piperidin-4-yl]methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one;hydrochloride
• CAS: 120013-40-3
• 化学式: C₂₄H₂₈FNO₃*ClH
• 分子量: 433.951
• InChiKey: RMINRSWFCXVFRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.92
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-氟溴苄 、 5,6-二甲氧基-2-(4-哌啶基)亚甲基-1-茚酮 在 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以72%的产率得到1-(3-Fluorobenzyl)-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride
  参考文献：
  名称：

  Cyclic amine compounds with activity against acetylcholinesterase

  摘要：

  一种环状胺化合物的定义式为：##STR1## 其中J为茚基、茚酰基、茚烯基、茚酰亚基、茚二酮基、四酰基基、苯并戊二酰基、茚醇基或其二价基团，K为苯基、芳基烷基或肉桂基，B为--(CHR22)r--，其中R22为H或甲基，--CO--(CHR22)r--，.dbd.(CH--CH.dbd.CH)b--，.dbd.CH--(CH2)c--或.dbd.(CH--CH)d.dbd.，并且包括T和Q的环为哌啶。该化合物可用于治疗老年性痴呆症。

  公开号：

  US04895841A1

文献信息

• Piperidine and piperazine compounds for use in the treatment of Alzheimer
  申请人：Eisai Co., Ltd.

  公开号：EP1116716A1

  公开（公告）日：2001-07-18

  A cyclic amine compound or a salt thereof is defined by the formula: in which J is (a) an optionally substituted group selected from (1) phenyl, (2) pyridyl, (3) pyrazyl, (4) quinolyl, (5) cyclohexyl, (6) quinoxalyl and (7) furyl; (b) a monovalent or divalent group, in which the phenyl may have a substituent(s) selected from the group consisting of (1) indanyl, (2) indanonyl, (3) indenyl, (4) indenonyl, (5) indanedionyl, (6) tetralonyl, (7) benzosuberonyl, (8) indanolyl and (9) C6H5-CO-CH(CH3)-; (c) a monovalent group derived from a cyclic amide compound; (d) a lower alkyl; or (e) a group of R21-CH=CH- in which R21 is hydrogen or a lower alkoxycarbonyl; B is a bridging group; T is a nitrogen; Q is nitrogen, carbon or >N→0; q is an integer of 1 to 3; K is hydrogen, an optionally substituted phenyl group, an arylalkyl in which the phenyl may have a substituent, cynnamyl, a lower alkyl, pyridylmethyl, a cycloalkylalkyl, adamantanemethyl, furylmethyl, a cycloalkyl, a lower alkoxycarbonyl or an acyl; and ----¯ shows a single bond or a double bond. The compound is useful for the preparation of pharmaceutical compositions and for medicaments effective against senile dementia.

  一个环状胺化合物或其盐的定义公式为：其中J是(a) 选择自(1) 苯基，(2) 吡啶基，(3) 吡唑基，(4) 喹啉基，(5) 环己基，(6) 喹噁啉基和(7) 呋喃基的可选取代基；(b) 一价或二价基团，其中苯基可以具有选自(1) 吲哚基，(2) 吲哚基丙烷基，(3) 茚基，(4) 茚基丙烷基，(5) 吲哚二酮基，(6) 四酮基，(7) 苯并戊二酰基，(8) 吲哚醇基和(9) C6H5-CO-CH(CH3)-的取代基；(c) 源自环状酰胺化合物的一价基团；(d) 较低的烷基；或(e) R21-CH=CH-中R21是氢或较低的烷氧羰基的基团；B是桥接基团；T是氮；Q是氮、碳或>N→0；q是1到3的整数；K是氢、可选取代苯基、芳基烷基，其中苯基可以具有取代基，肉桂酸基，较低的烷基，吡啶甲基，环状烷基烷基，金刚烷基甲基，呋喃基甲基，环状烷基，较低的烷氧羰基或酰基；而----¯表示单键或双键。该化合物用于制备药物组合物和用于治疗老年痴呆症的药物。
• Sigma receptor binding agent containing indanone derivative
  申请人：Iimura Yoichi

  公开号：US20090137629A1

  公开（公告）日：2009-05-28

  A method for treatment of a mental disorder containing the step of administering a therapeutically effective amount of a sigma receptor binding agent containing an indanone compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. The variables of formula (I) are recited in the present specification.

  一种治疗精神障碍的方法，包括以下步骤：给予治疗有效量的sigma受体结合剂，该结合剂包含以下式子（I）所表示的indanone化合物，其药理学上可接受的盐或水合物。式子（I）的变量在本说明书中已列出。
• 1,4-Substituted piperidines as acetylchozinesterase inhibitors and their use for the treatment of Alzheimer's disease
  申请人：Eisai Co., Ltd.

  公开号：EP0579263A1

  公开（公告）日：1994-01-19

  Cyclic amines are provided of the formula: wherein J is: (a) a group, substituted or unsubstituted, selected from the group consisting of (1) phenyl, (2) pyridyl, (3) pyrazyl, (4) quinolyl, (5) cyclohexyl, (6) quinoxalyl and (7) furyl; (b) a monovalent group derived from a cyclic amide compound; (c) a lower alkyl or (d) a group of R²¹-CH=CH- in which R²¹ is hydrogen or a lower alkoxycarbonyl;    K is phenyl, an arylalkyl or cynnamyl;    B is -(CHR22)r-, R22 being H or methyl, -CO-(CHR22)r-, =(CH-CH=CH)b-, =CH-(CH2)c- or =(CH-CH)d=; and the ring including T and Q is piperidine. The compound is useful for the preparation of pharmaceutical compositions and for medicaments effective against senile dementia.

  环胺的化学式为 其中 J 为 (a) 一个取代或未取代的基团，选自由(1)苯基、(2)吡啶基、(3)苄基、 (4)喹啉基、(5)环己基、(6)喹喔啉基和(7)呋喃基组成的组； (b) 由环酰胺化合物衍生的一价基团； (c) 低级烷基或 (d) R²¹-CH=CH- 的基团，其中 R²¹ 是氢或低级烷氧羰基； K 是苯基、芳烷基或炔酰胺基； B是-(CHR22)r-，R22是氢或甲基，-CO-(CHR22)r-，=(CH-CH=CH)b-，=CH-(CH2)c-或=(CH-CH)d=；包括T和Q的环是哌啶。 该化合物可用于制备药物组合物和对老年痴呆症有效的药物。
• 4-[2-indanyl-1-one]alkylpiperidines as anticholinergic agents
  申请人：Eisai Co., Ltd.

  公开号：EP0673927A1

  公开（公告）日：1995-09-27

  A cyclic amine compound is defined by the formula: in which J is indanyl, indanonyl, indenyl, indenonyl, indanedionyl, tetralonyl, benzosuberonyl, indanolyl or a divalent group thereof, K is phenyl, an arylalkyl or cynnamyl, B is -(CHR22)r-, R22 being H or methyl, -CO-(CHR22)r-, =(CH-CH=CH)b-, =CH-(CH2)c- or =(CH-CH)d= and the ring including T and Q is piperidine. The compound is useful for the preparation of pharmaceutical compositions and for medicaments effective against senile dementia.

  环胺化合物的定义如下式所示 其中 J 是茚基、茚壬基、茚基、茚烯基、茚二壬基、四壬基、苯并琥珀酰基、 茚醇基或其二价基团，K 是苯基、B是-(CHR22)r-，R22是H或甲基、-CO-(CHR22)r-、=(CH-CH=CH)b-、=CH-(CH2)c-或=(CH-CH)d=，包括T和Q的环是哌啶。该化合物可用于制备药物组合物和对老年痴呆症有效的药物。
• SIGMA RECEPTOR BINDER CONTAINING INDANONE DERIVATIVE
  申请人：Eisai Co., Ltd.

  公开号：EP1468684A1

  公开（公告）日：2004-10-20

  The present invention provides an indanone derivative and an excellent sigma receptor binding agent comprising an indanone derivative. More specifically, it provides a sigma receptor binding agent comprising an indanone derivative represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate of them. In the formula (I), R1, R2, R3 and R4 are the same as or different from each other and each represents hydrogen atom, a halogen atom, hydroxyl group, nitrile group, a C1-6 alkyl group which may be substituted, a cycloalkyl group having three to eight carbon atoms which may be substituted, a C1-6 alkoxy group which may be substituted, a cycloalkoxy group having three to eight carbon atoms which may be substituted, an acyl group having one to six carbon atoms which may be substituted, a C1-6 alkoxycarbonyl group which may be substituted, a C1-6 alkylaminocarbonyloxy group which may be substituted, a di(C1-6 alkyl)aminocarbonyloxy group which may be substituted, nitro group, an amino group which may be substituted, an amido group which may be substituted, mercapto group or a thio-C1-6 alkoxy group which may be substituted, and further R1 with R2, R2 with R3, or R3 with R4 may together form an aliphatic ring, an aromatic ring, a heterocyclic ring or an alkylenedioxy ring; the partial structure: represents a group represented by >CH-CH2-, >C=CH- or >C(-R7)-CH2-; m represents an integer of 0 or 1 to 5; and R5 represents hydrogen atom, a C1-6 alkyl group which may be substituted, a C2-6 alkenyl group which may be substituted, a C2-6 alkynyl group which may be substituted, a cycloalkyl group having three to eight carbon atoms which may be substituted, a 2,2-(alkylenedioxy)ethyl group or a group represented by the formula: (wherein the ring C represents benzene ring, an aliphatic ring or a heterocyclic ring; R6s are the same as or different from each other and each represents hydrogen atom, a halogen atom, hydroxyl group, nitrile group, a C1-6 alkyl group which may be substituted, a C2-6 alkenyl group which may be substituted, a C2-6 alkynyl group which may be substituted, a cycloalkyl group having three to eight carbon atoms which may be substituted, a C1-6 alkoxy group which may be substituted, a C1-6 alkoxyalkoxy group which may be substituted, an aryloxy group which may be substituted or an aralkyloxy group which may be substituted, and further two of R6s may together form an aliphatic ring, an aromatic ring, a heterocyclic ring or an alkylenedioxy ring; R7 represents a halogen atom, hydroxyl group, a C1-6 alkyl group which may be substituted, a C1-6 alkoxy group, nitrile group, a halogeno-C1-6 alkyl group, a hydroxyl-C1-6 alkyl group, a cyano-C1-6 alkyl group, an amino-C1-6 alkyl group, nitro group, azide group, an amino group which may be substituted, a carbamoyl group which may be substituted, a carboxyl group which may be substituted, mercapto group or a thio-C1-6 alkoxy group; and n represents an integer of 1 to 5), provided that 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine, a pharmacologically acceptable salt thereof or a hydrate of them are excluded.

  本发明提供了一种茚满酮衍生物和一种包含茚满酮衍生物的优良σ受体结合剂。更具体地说，本发明提供了一种σ受体结合剂，它由下式所代表的茚酮衍生物、其药理学上可接受的盐或它们的水合物组成。 在式 (I) 中，R1、R2、R3 和 R4 彼此相同或不同，各自代表氢原子、卤素原子、羟基、腈基、可被取代的 C1-6 烷基、具有三至八个碳原子且可被取代的环烷基、可被取代的 C1-6 烷氧基、具有三至八个碳原子且可被取代的环烷氧基、具有一至六个碳原子且可被取代的酰基、可被取代的 C1-6 烷氧基羰基、可被取代的 C1-6 烷基氨基羰氧基、可被取代的二（C1-6 烷基）氨基羰氧基、硝基、可被取代的氨基、可被取代的酰胺基、巯基或可被取代的硫代-C1-6 烷氧基，此外，R1 与 R2、R2 与 R3 或 R3 与 R4 可共同形成脂肪环、芳香环、杂环或烷基二氧基环；部分结构： 代表由 >CH-CH2-、>C=CH- 或 >C(-R7)- -代表的基团；m 代表 0 或 1 至 5 的整数；R5 代表氢原子、可被取代的 C1-6 烷基、可被取代的 C2-6 烯基、可被取代的 C2-6 烷基、可被取代的具有 3 至 8 个碳原子的环烷基、2,2-(烷基二氧基)乙基或由式...代表的基团： (其中环 C 代表苯环、脂肪环或杂环；R6s 彼此相同或不同，各自代表氢原子、卤素原子、羟基、腈基、可被取代的 C1-6 烷基、可被取代的 C2-6 烯基、可被取代的 C2-6 烷基、具有三至八个碳原子的可被取代的环烷基、可被取代的 C1-6 烷氧基、可被取代的 C1-6 烷氧基、可被取代的芳氧基或可被取代的芳烷氧基，另外两个 R6 可共同形成脂肪环、芳香环、杂环或烷二氧基环；R7 代表卤素原子、羟基、可被取代的 C1-6 烷基、C1-6 烷氧基、腈基、卤素-C1-6 烷基、羟基-C1-6 烷基、氰基-C1-6 烷基、氨基-C1-6 烷基、硝基、叠氮基、可被取代的氨基、可被取代的氨基甲酰基、可被取代的羧基、巯基或硫代-C1-6 烷氧基；和 n 代表 1 至 5 的整数），但不包括 1-苄基-4-[(5,6-二甲氧基-1-茚酮)-2-基]甲基哌啶、其药理学上可接受的盐或它们的水合物。